Inge Kemper

1.7k total citations
11 papers, 461 citations indexed

About

Inge Kemper is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Inge Kemper has authored 11 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Cancer Research and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Inge Kemper's work include HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Inge Kemper is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Inge Kemper collaborates with scholars based in Netherlands, Belgium and United States. Inge Kemper's co-authors include Ingrid A.M. Mandjes, Gabe S. Sonke, Sabine C. Linn, Erik van Werkhoven, Mette S. van Ramshorst, Irma M. Oving, Aafke H. Honkoop, Caroline M.P.W. Mandigers, Jelle Wesseling and Lidwine W. Tick and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Inge Kemper

11 papers receiving 455 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Inge Kemper Netherlands	7	381	268	94	88	52	11	461
Antonia Márquez Spain	10	294 0.8×	134 0.5×	71 0.8×	99 1.1×	32 0.6×	15	444
Maeve Waldron-Lynch United States	10	427 1.1×	248 0.9×	95 1.0×	228 2.6×	16 0.3×	21	564
Karen McAdam United Kingdom	11	265 0.7×	124 0.5×	66 0.7×	55 0.6×	20 0.4×	23	343
S. Kahlert Germany	6	445 1.2×	299 1.1×	132 1.4×	138 1.6×	12 0.2×	12	539
Marie-Jeanne TFD Vrancken Peeters Netherlands	6	293 0.8×	273 1.0×	110 1.2×	78 0.9×	6 0.1×	9	399
Leena Helle Finland	7	457 1.2×	248 0.9×	155 1.6×	84 1.0×	15 0.3×	11	520
Lauren Nye United States	9	270 0.7×	115 0.4×	34 0.4×	76 0.9×	46 0.9×	37	369
Christopher Stokoe United States	9	480 1.3×	254 0.9×	189 2.0×	134 1.5×	8 0.2×	17	547
V. Diéras France	8	261 0.7×	84 0.3×	38 0.4×	65 0.7×	29 0.6×	25	321
Amna Sheri United Kingdom	9	200 0.5×	147 0.5×	23 0.2×	72 0.8×	19 0.4×	20	306

Countries citing papers authored by Inge Kemper

Since Specialization

Citations

This map shows the geographic impact of Inge Kemper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge Kemper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge Kemper more than expected).

Fields of papers citing papers by Inge Kemper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge Kemper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge Kemper. The network helps show where Inge Kemper may publish in the future.

Co-authorship network of co-authors of Inge Kemper

This figure shows the co-authorship network connecting the top 25 collaborators of Inge Kemper. A scholar is included among the top collaborators of Inge Kemper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inge Kemper. Inge Kemper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Voorwerk, Leonie, Sara Balduzzi, Roberto Salgado, et al.. (2023). Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial. The Breast. 70. 76–81. 15 indexed citations

Voorwerk, Leonie, Karolina Sikorska, Inge Kemper, et al.. (2021). 90TiP Monalizumab and trastuzumab in metastatic HER2-positive breast cancer: MIMOSA-trial. Annals of Oncology. 32. S59–S59. 3 indexed citations

Voorwerk, Leonie, Hugo M. Horlings, Karolina Sikorska, et al.. (2021). LBA3 Atezolizumab with carboplatin as immune induction in metastatic lobular breast cancer: First results of the GELATO-trial. Annals of Oncology. 32. S58–S58. 6 indexed citations

Voort, Anna van der, Mette S. van Ramshorst, Erik van Werkhoven, et al.. (2021). Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of DualERBB2Blockade in Patients WithERBB2-Positive Breast Cancer. JAMA Oncology. 7(7). 978–978. 76 indexed citations

Voorwerk, Leonie, Hugo M. Horlings, Inge Kemper, et al.. (2020). 135TiP GELATO-trial: Assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer. Annals of Oncology. 31. S61–S61. 4 indexed citations

Voort, Anna van der, Mette S. van Ramshorst, Erik van Werkhoven, et al.. (2020). Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.. Journal of Clinical Oncology. 38(15_suppl). 501–501. 24 indexed citations

Ramshorst, Mette S. van, Anna van der Voort, Erik van Werkhoven, et al.. (2018). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 19(12). 1630–1640. 245 indexed citations

Kok, Marleen, Leonie Voorwerk, Hugo M. Horlings, et al.. (2018). Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.. Journal of Clinical Oncology. 36(15_suppl). 1012–1012. 34 indexed citations

Kok, Marleen, Hugo M. Horlings, T. Wiersma, et al.. (2017). Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial. Annals of Oncology. 28. v608–v608. 21 indexed citations

10.

Ramshorst, Mette S. van, Erik van Werkhoven, Ingrid A.M. Mandjes, et al.. (2017). A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03).. Journal of Clinical Oncology. 35(15_suppl). 507–507. 5 indexed citations

11.

Ramshorst, Mette S. van, Erik van Werkhoven, Aafke H. Honkoop, et al.. (2016). Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. The Breast. 29. 153–159. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact